BRAF and cancer: Similarly, BRAF inhibitor decreased pERK in cells with BRAFV600E mutations (Figure 3 Panel 1,D), but as expected, caused a paradoxical increase in pERK in the BRAFWT cancer cells (Figure 3 Panel 2,D) [28].